6-[(4-Azido-3-iodophenyl)methyl]-2,6-dihydro-2-methyl-4-(2-methylpropyl)-1H-pyrrolo[3,4-d]pyridazin-1-one | 873327-57-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并[3，4-d]哒嗪
• 英文名称: 6-[(4-Azido-3-iodophenyl)methyl]-2,6-dihydro-2-methyl-4-(2-methylpropyl)-1H-pyrrolo[3,4-d]pyridazin-1-one
• 英文别名: 6-[(4-azido-3-iodophenyl)methyl]-3-methyl-1-(2-methylpropyl)pyrrolo[3,4-d]pyridazin-4-one
• CAS: 873327-57-2
• 化学式: C₁₈H₁₉IN₆O
• 分子量: 462.293
• InChiKey: IQUBUSDCIITPSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  hexamethyl ditin 、 tetrakis triphenylphosphine Pd ⁽⁰⁾ 、 6-[(4-Azido-3-iodophenyl)methyl]-2,6-dihydro-2-methyl-4-(2-methylpropyl)-1H-pyrrolo[3,4-d]pyridazin-1-one 生成 6-[(4-Azido-3-(trimethylstannyl)phenyl)methyl]-2,6-dihydro-2-methyl-4-(2-methylpropyl)-1H-pyrrolo[3,4-d]pyridazin-1-one
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Inhibitors of monocarboxylate transport
  申请人：——

  公开号：US20040072746A1

  公开（公告）日：2004-04-15

  Methods of screening compounds for their ability to inhibit monocarboxylate transport, and methods of making and using such inhibitors to treat disorders associated with cellular proliferation, e.g., immune-mediated disorders and cancer.

  筛选化合物抑制单羧酸转运能力的方法，以及制备和使用这些抑制剂治疗与细胞增殖相关的疾病的方法，例如免疫介导性疾病和癌症。
• SCREENING METHOD
  申请人：AstraZeneca AB

  公开号：EP1697744A1

  公开（公告）日：2006-09-06
• [EN] SCREENING METHOD<br/>[FR] METHODE DE CRIBLAGE
  申请人：ASTRAZENECA AB

  公开号：WO2005054852A1

  公开（公告）日：2005-06-16

  This invention arises from the discovery that compounds capable of blocking cellular monocarboxylate transport can inhibit lymphocyte proliferation, offering up these compounds as therapeutic agents in various immune-mediated disorders and cancers. Accordingly, this invention relates, inter alia, to methods of screening compounds for their ability to treat certain cancers and immune-mediated disorders, particularly transplant rejection and rheumatoid arthritis. The invention also relates to methods of treating these diseases by administering a compound or compounds capable of inhibiting monocarboxylate transport and the use of monocarboxylate transport inhibitor compounds in treating such diseases.